What type of study is this?

This is a Meta-Analysis study (also classified as: Literature Review).

August 16, 2025Frontiers in ImmunologyOpen Access

Meta-analysis of multi-center transcriptomic profiles and machine learning reveal phospholipase Cβ4 as a Wnt/Ca²+ signaling mediator in glioblastoma immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis identifies phospholipase Cβ4's role in glioblastoma, suggesting new immunotherapy targets.

Phospholipase Cβ4 emerges as a potential tumor suppressor related to glioblastoma progression, enhancing therapy options.
The study indicates a negative correlation between PLCB4 levels and tumor grade, emphasizing its relevance in glioblastoma cases.
Utilizing meta-analysis and gene co-expression networks, critical insights into PLCB4's signaling pathways were obtained.
Identifying small molecules targeting PLCB4 could provide novel therapeutic strategies against aggressive glioblastoma.

Song et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

August 16, 2025Frontiers in ImmunologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis identifies phospholipase Cβ4's role in glioblastoma, suggesting new immunotherapy targets.

Phospholipase Cβ4 emerges as a potential tumor suppressor related to glioblastoma progression, enhancing therapy options.
The study indicates a negative correlation between PLCB4 levels and tumor grade, emphasizing its relevance in glioblastoma cases.
Utilizing meta-analysis and gene co-expression networks, critical insights into PLCB4's signaling pathways were obtained.
Identifying small molecules targeting PLCB4 could provide novel therapeutic strategies against aggressive glioblastoma.

Song et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark